|
New Report from PharmaPlus: HIV Pipelines & Deals
At the end
of November 2003 the joint United Nations Program on HIV/AIDS and the World
Health Organization presented the latest figures on HIV-infection. Their
conclusion was that the global AIDS epidemic still shows no signs of abating.
While prevention of HIV is a main focus to finally stop the AIDS epidemic, until
now no approved prevention products have reached the market. On the other hand a
growing number of HIV therapeutics is since several years introduced on the
market. Up to 2003 reverse transcriptase inhibitors and protease inhibitors were
the only two product classes available on the market. Early 2003 the first
fusion inhibitor entered the market. Next to these products, a growing number of
drugs are under development for both HIV prevention and therapy. Categorized
according to the various succeeding steps in HIV-infection this report reviews
more than 100 drugs currently under development. Deals closed in 2003 for these
products are highlighted. Company snapshots for over 70 public and private
companies are presented. These snapshots include contact details, venture
capital companies involved for private companies c.q. limited financial
information for public companies, HIV research focus, HIV products in
development and HIV strategic alliances with industrial partners.
Click
here to order HIV
Pipelines and Deals
Reasons to buy the report:
a. quick market insight into
development pipelines
b. identification of potential
collaboration partners
c. identification of VC companies
investing in HIV products
Report will be of interest to
business development and VC professionals and CROs evaluating strategic
opportunities with regard to strategic alliances, financing and identification
of new clients and / or products.
Number of pages: 108
Published: Dec 2003
Format: Printed
Price:
$1,895.00 - Click here to order HIV
Pipelines and Deals
Table
of Content: HIV
pipelines & Deals
|
1. Introduction
2. HIV Products under development
2.1 The HIV infection process
2.2 Therapeutics under development for HIV infection
2.2.1 Entry/Fusion inhibitors
2.2.2 Plasma delipidation
2.2.3 Nuclear importation inhibitors
2.2.4 Reverse transcriptase inhibitors
2.2.5 Integrase inhibitors
2.2.6 Transcription inhibitors
2.2.7 Protease inhibitors
2.2.8 Maturation inhibitors
2.2.9 Immunomodulators
2.2.10 Others
2.3 Prevention of HIV infection
2.3.1 Vaginal microbicides
2.3.2 Vaccines
3. Deal activity 2003
Appendices
Appendix 1: Company snapshots
Acceleration biopharmaceuticals
Achillion Pharmaceuticals
Advanced Life Sciences
Aethlon Medical
AlphaVax
AnorMED
Avant Immunotherapeutics
Aventis Pharma
Axxima Pharmaceuticals
Bavarian Nordic
BioDelivery Sciences
Biosyn
Biota Holdings
BioVex
Boehringer Ingelheim
Bristol Myers Squibb
Chiron
CytoDyn
CytRx Corporation
Dimethaid Research
EMD Pharmaceuticals
Enzo Biochem
Epimmune
FIT Biotech
GeoVax
Gilead Sciences
GlaxoSmithKline
Hemispherx BioPharma
HIV-VAC
Hollis-Eden Pharmaceuticals
Hybridon
Idenix Pharmaceuticals
The Immune Response Corporation
Indevus Pharmaceuticals
International Therapeutics
Johnson & Johnson
Lauras
Lipid Sciences
Maxygen
Medarex
Medivir
Merck & Co.
ML Laboratories
MolMed
Myriad Genetics
Oxford BioMedica
Oxxon Pharmaccines
Panacos Pharmaceuticals
Pfizer
Polydex Pharmaceuticals
The Population Council
Praecis Pharmaceuticals
Procyon Biopharma
Progenics Pharmaceuticals
PTC Therapeutics
Redox Pharmaceutical Corporation
Roche
Samaritan Pharmaceuticals
Schering-Plough Corporation
Shire Pharmaceuticals
Tanox
Trimeris
Tripep
United Biomedical
URRMA Biopharma
VaxGen
Vertex Pharmaceuticals
VGX Pharmaceuticals
Virocell
Viral Genetics
Virax Holdings
VIRxSYS
Appendix 2: Products listed by development status
Appendix 3: Venture capital companies |
Click
here to order HIV
Pipelines and Deals
| 